Pharma BD Deal Intelligence

Third Rock Ventures / Funnel Biosciences

2026 · Co-Development · $2.2B · Complete

Funnel Biosciences, a Beijing-based AI-driven biologics discovery company founded in February 2026, entered a multi-target antibody discovery collaboration with Third Rock Ventures. Funnel will apply its epitope-guided AI antibody discovery platform against drug targets nominated by Third Rock Ventures, with an emphasis on membrane targets and candidates with picomolar affinity, favorable developability and low immunogenicity. Funnel receives an undisclosed platform access fee and is eligible for additional payments totaling up to approximately $2.16 billion, subject to conditions. The deal is notable as only the second direct drug-discovery collaboration undertaken by Third Rock Ventures, which has historically operated as a company incubator rather than a discovery partner.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →